Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Cancer Discov. 2014 Feb;4(2):152–154. doi: 10.1158/2159-8290.CD-13-1049

Figure 1. Mechanisms of transformation of FGFR1-amplified SQLCs.

Figure 1

FGF ligands produced by tumor cells support the growth of FGF-amplified cancer cells and can potentially modulate sensitivity to FGFR inhibitors in a dose-dependent manner. High expression levels of MYC in these tumor cells confer greater sensitivity to FGFR inhibitors than low levels leading to cell death and tumor regression.